<DOC>
	<DOCNO>NCT02964377</DOCNO>
	<brief_summary>This single center open-label pilot study enroll 15 non-ambulatory child Duchenne muscular dystrophy least 8 year age demonstrate pre-clinical cardiomyopathy ( defined cardiac ejection fraction &gt; 55 % abnormal LV strain cardiac MRI ) . They receive ( + ) -epicatechin one three dose 8-week dose-ranging study assessment baseline , 2 Weeks , 4weeks , 8 week . The study determine optimal dose future cardiac efficacy study base serum / plasma biomarker response use follistatin : myostatin ratio , nitrite/nitrate ratio , cardiac troponins cardiac BNP . Secondary endpoint include additional biomarker assessment SOMAscanTM , cardiac functional evaluation cardiac MRI ( LV strain ) , echocardiogram ( LV strain speckle tracking ) measure strength , range motion mobility , clinical safety assessment . Results secondary endpoint analysis use refine design subsequent clinical trial power detect change clinical outcome .</brief_summary>
	<brief_title>Plus Epicatechin Duchenne Muscular Dystrophy Non-ambulatory Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Male Age 8 year 17 year NonAmbulatory ( unable complete 10m run/walk 10 ) Weight &lt; /=100Kg Diagnosis DMD confirm least one following : Dystrophin immunofluorescence and/or immunoblot show complete dystrophin deficiency , clinical picture consistent typical DMD , Gene deletion test positive ( miss one exon ) dystrophin gene , read frame predict 'outofframe ' , clinical picture consistent typical DMD , Complete dystrophin gene sequence show alteration ( point mutation , duplication , mutation result stop codon mutation ) definitely associate DMD , typical clinical picture DMD , Positive family history DMD confirm one criterion list sibling maternal uncle , clinical picture typical DMD . Cardiac ejection fraction &gt; 55 % echocardiogram Use nutritional , herbal antioxidant supplement take intent maintain improve skeletal muscle strength functional mobility discontinue least 4 week prior screen ( daily multivitamin use acceptable ) . Glucocorticoid therapy , use , must stable weightbased dose least 3 month prior enrollment Cardiac therapy , use , include prophylactic ACE inhibitor , aldosterone receptor antagonist ( e.g . spironolactone , eplerenone , etc . ) , and/or betablocker therapy , must stable 3 month prior enrollment . Hematology profile within normal range . Baseline laboratory safety chemistry profile within typical range DMD ( elevate ALT / AST acceptable absence elevate GGT , elevate CK acceptable ) . Inability complete cardiac strength , range motion mobility assessment per protocol Current enrollment another treatment clinical trial . History significant concomitant illness significant impairment renal hepatic function . Use regular daily aspirin medication antiplatelet effect within 3 week first dose study medication . Cardiac symptom , opinion investigator , may suggestive imminent moderate severe cardiac event , irrespective LVEF .</criteria>
	<gender>Male</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>muscle disease</keyword>
	<keyword>Duchenne muscular dystrophy</keyword>
	<keyword>cardiomyopathy</keyword>
</DOC>